EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Panel-Based Genetic Testing in a Consecutive Series of Individuals with Inherited Retinal Diseases in Australia: Identifying Predictors of a Diagnosis

Alexis Ceecee Britten-Jones iD, Doron G Hickey, Thomas L Edwards, Lauren N Ayton

Genes · 2025

DOI: 10.3390/genes16080888 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genes, 2025. Verfasst von Alexis Ceecee Britten-Jones und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Optometry and Vision Sciences, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville 3010, Australia. Hauptthemen laut MEDLINE: Genetic Testing, Retinal Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The University of Melbourne, National Health and Medical Research Council, University of Melbourne Research Fellowship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Genetic testing is important for diagnosing inherited retinal diseases (IRDs), but further evidence is needed on the utility of singleton genetic testing in an Australian cohort.

Methods

A consecutive series of individuals with clinically diagnosed IRDs without prior genetic testing underwent commercial panel-based sequencing (Invitae or Blueprint Genetics), clinical assessment, and multimodal imaging. Retinal images were graded using the Human Phenotype Ontology terms. Binary logistic regression was used to evaluate clinical predictors of a positive molecular diagnosis.

Results

Among 140 participants (mean age 49 ± 19 years), genetic testing was undertaken, on average, 23 ± 17 years after the initial clinical IRD diagnosis. Of the 60% who received a probable molecular diagnosis, 40% require further phase testing, highlighting the limitations of singleton genetic testing. USH2A, ABCA4, and RPGR were the most common encountered genes; 67% of the probably solved participants had causative genes with targeted experimental treatments in ongoing human clinical trials. Symptom onset before the age of 30 (OR = 3.06 [95% CI: 1.34–7.18]) and a positive IRD family history (OR = 2.87 [95% CI: 1.27–6.78]) were each associated with higher odds of receiving a molecular diagnosis. Diagnostic rates were comparable across retinal imaging phenotypes (atrophy and autofluorescence patterns in widespread IRD, and the extent of dystrophy in macular IRDs).

Conclusions

In an Australian IRD population without prior genetic testing, commercial panels yielded higher diagnostic rates in individuals with IRD onset before the age of 30 and those with an IRD family history. Further research is needed to understand the genetic basis of IRDs, especially isolated and late-onset cases, to improve diagnosis and access to emerging therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TestingRetinal DiseasesHumansMaleMiddle AgedFemaleAustraliaAdultAgedYoung AdultATP-Binding Cassette TransportersExtracellular Matrix Proteins

Stichwörter der Autor:innen

diagnostic utilitygenetic testinginherited retinal diseasesmacular dystrophynext generation sequencingretinal dystrophyretinitis pigmentosatargeted panels

Substanzen

ABCA4 protein, humanUSH2A protein, humanATP-Binding Cassette TransportersExtracellular Matrix Proteins

Autor:innen und Institutionen

  • Department of Optometry and Vision Sciences, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville 3010, Australia.
  • Department of Surgery (Ophthalmology), Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville 3010, Australia.
  • Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne 3002, Australia.

ORCID-Profile: Alexis Ceecee Britten-Jones

Förderung

  • The University of Melbourne
  • National Health and Medical Research Council
  • University of Melbourne Research Fellowship
  • Annemarie Mankiewicz-Zelkin Fellowship
  • Centre for Eye Research Australia Strategic Grant
  • Angior Family Foundation
  • CASS Foundation
  • Novartis Pharmaceuticals Corporation

Zitieren

APA

Britten-Jones, A. C., Hickey, D. G., Edwards, T. L., & Ayton, L. N. (2025). Panel-Based Genetic Testing in a Consecutive Series of Individuals with Inherited Retinal Diseases in Australia: Identifying Predictors of a Diagnosis. Genes. https://doi.org/10.3390/genes16080888

Vancouver

Britten-Jones AC, Hickey DG, Edwards TL, Ayton LN. Panel-Based Genetic Testing in a Consecutive Series of Individuals with Inherited Retinal Diseases in Australia: Identifying Predictors of a Diagnosis. Genes. 2025. doi:10.3390/genes16080888

BibTeX
@article{BrittenJones2025,
  author = {Britten-Jones, Alexis Ceecee and Hickey, Doron G and Edwards, Thomas L and Ayton, Lauren N},
  title = {Panel-Based Genetic Testing in a Consecutive Series of Individuals with Inherited Retinal Diseases in Australia: Identifying Predictors of a Diagnosis},
  journal = {Genes},
  year = {2025},
  doi = {10.3390/genes16080888}
}
Kostenlos starten →